These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18799113)

  • 1. Inhaled iloprost for the treatment of Raynaud's phenomenon.
    Pakozdi A; Howell K; Wilson H; Fox S; Gonzalez L; Black CM; Denton CP
    Clin Exp Rheumatol; 2008; 26(4):709. PubMed ID: 18799113
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
    Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E
    Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iloprost treatment of finger gangrene in a patient with Raynaud's syndrome.
    Levy Y; Sherer Y; Shoenfeld Y
    Isr Med Assoc J; 2000 Dec; 2(12):960-1. PubMed ID: 11344792
    [No Abstract]   [Full Text] [Related]  

  • 5. Raynaud's of the gut? Systemic sclerosis-associated microvascular ischaemic colitis responsive to intravenous iloprost.
    Pratap K; Penglase R; Roper E; Stoita A
    Rheumatology (Oxford); 2024 Aug; 63(8):e219-e221. PubMed ID: 38290764
    [No Abstract]   [Full Text] [Related]  

  • 6. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E; Virgilio S; Ghirardi R; Martinelli M
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Iloprost for the treatment of systemic sclerosis].
    Hachulla E; Launay D; Hatron PY
    Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
    Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is iloprost effective in secondary Raynaud's phenomenon?
    Lustig N; Rada G
    Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
    Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
    Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iloprost infusion through elastomeric pump for the outpatient treatment of severe Raynaud's phenomenon and digital ulcers - a single centre experience.
    Duarte AC; Barbosa L; Santos MJ; Cordeiro A
    Acta Reumatol Port; 2018; 43(3):237-238. PubMed ID: 30414374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raynaud's phenomenon affecting the tongue of a patient with scleroderma.
    Bridges MJ; Kelly CA
    Ann Rheum Dis; 2002 May; 61(5):472. PubMed ID: 11959778
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA).
    Fraticelli P; Martino GP; Murri M; Mattioli M; Gabrielli A
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):173-178. PubMed ID: 28869415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raynaud's phenomenon: its relevance to scleroderma.
    Belch JJ
    Ann Rheum Dis; 1991 Nov; 50 Suppl 4(Suppl 4):839-45. PubMed ID: 1750795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.